دورية أكاديمية
أعرض في EDS

Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines.

التفاصيل البيبلوغرافية
العنوان: Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines.
المؤلفون: Borrajo ML; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain.; IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain., Lou G; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.; IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain., Anthiya S; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.; IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain., Lapuhs P; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.; IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain., Álvarez DM; Biofarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain., Tobío A; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain.; IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain., Loza MI; Biofarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain., Vidal A; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.; IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain., Alonso MJ; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain. mariaj.alonso@usc.es.; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain. mariaj.alonso@usc.es.; IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain. mariaj.alonso@usc.es.
المصدر: Drug delivery and translational research [Drug Deliv Transl Res] 2024 Aug; Vol. 14 (8), pp. 2046-2061. Date of Electronic Publication: 2024 May 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York : Springer
مواضيع طبية MeSH: Administration, Intranasal* , Nanocapsules*/chemistry , mRNA Vaccines* , Emulsions* , COVID-19 Vaccines*/administration & dosage , COVID-19 Vaccines*/immunology, Animals ; Mice ; COVID-19/prevention & control ; Nanoparticles/administration & dosage ; Nanoparticles/chemistry ; Humans ; SARS-CoV-2/immunology ; Female ; Quaternary Ammonium Compounds/chemistry ; Mice, Inbred BALB C ; Fatty Acids, Monounsaturated/chemistry ; RNA, Messenger/administration & dosage ; Drug Carriers/chemistry ; Drug Carriers/administration & dosage
مستخلص: The global emergency of coronavirus disease 2019 (COVID-19) has spurred extensive worldwide efforts to develop vaccines for protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our contribution to this global endeavor involved the development of a diverse library of nanocarriers, as alternatives to lipid nanoparticles (LNPs), including nanoemulsions (NEs) and nanocapsules (NCs), with the aim of protecting and delivering messenger ribonucleic acid (mRNA) for nasal vaccination purposes. A wide range of prototypes underwent rigorous screening through a series of in vitro and in vivo experiments, encompassing assessments of cellular transfection, cytotoxicity, and intramuscular administration of a model mRNA for protein translation. As a result, two promising candidates were identified for nasal administration. One of them was a NE incorporating a combination of an ionizable lipid (C12-200) and cationic lipid (DOTAP), both intended to condense mRNA, along with DOPE, which is known to facilitate endosomal escape. This NE exhibited a size of 120 nm and a highly positive surface charge (+ 50 mV). Another candidate was an NC formulation comprising the same components and endowed with a dextran sulfate shell. This formulation showed a size of 130 nm and a moderate negative surface charge (-16 mV). Upon intranasal administration of mRNA encoding for ovalbumin (mOVA) associated with optimized versions of the said NE and NCs, a robust antigen-specific CD8 + T cell response was observed. These findings underscore the potential of NEs and polymeric NCs in advancing mRNA vaccine development for combating infectious diseases.
(© 2024. The Author(s).)
References: Nanomedicine (Lond). 2012 Nov;7(11):1667-81. (PMID: 22812708)
J Control Release. 2006 Jun 28;113(2):164-72. (PMID: 16759732)
J Control Release. 2022 Oct;350:256-270. (PMID: 35963467)
Int J Pharm. 2009 Dec 1;382(1-2):205-14. (PMID: 19660537)
Sci Adv. 2023 Sep 22;9(38):eadh1655. (PMID: 37738334)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
NPJ Vaccines. 2023 May 13;8(1):68. (PMID: 37179389)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Cell. 2020 Sep 3;182(5):1271-1283.e16. (PMID: 32795413)
Pharm Res. 2022 Jan;39(1):105-114. (PMID: 35080707)
Eur J Pharm Biopharm. 2015 Nov;97(Pt A):51-9. (PMID: 26455338)
Nature. 2022 Feb;602(7896):294-299. (PMID: 34818667)
Mol Ther. 2022 May 4;30(5):1850-1868. (PMID: 35189345)
Semin Immunol. 2017 Dec;34:78-102. (PMID: 29032891)
Methods Mol Biol. 2017;1601:43-59. (PMID: 28470516)
Int J Pharm. 2021 Jun 15;603:120686. (PMID: 33964339)
J Control Release. 2013 Dec 28;172(3):773-81. (PMID: 24076340)
Nature. 2020 Oct;586(7830):567-571. (PMID: 32756549)
Part Fibre Toxicol. 2010 Sep 11;7:25. (PMID: 20831820)
Nat Rev Mater. 2021;6(12):1078-1094. (PMID: 34394960)
J Pharm Sci. 2012 Jan;101(1):233-44. (PMID: 21953499)
Nat Immunol. 2022 Feb;23(2):186-193. (PMID: 35105982)
Commun Biol. 2021 Aug 11;4(1):956. (PMID: 34381159)
Cytometry B Clin Cytom. 2015 Jan;88(1):6-20. (PMID: 25338522)
Gene Ther. 2019 Sep;26(9):363-372. (PMID: 31300730)
Biochim Biophys Acta. 2015 Oct;1848(10 Pt A):1996-2001. (PMID: 26112463)
Mol Pharm. 2011 Jun 6;8(3):774-87. (PMID: 21417235)
Adv Drug Deliv Rev. 2009 Feb 27;61(2):140-57. (PMID: 19121350)
J Microencapsul. 2013;30(3):283-94. (PMID: 22994538)
Cell Prolif. 2015 Aug;48(4):465-74. (PMID: 26017818)
Int J Pharm X. 2019 Aug 13;1:100030. (PMID: 31517295)
ACS Appl Mater Interfaces. 2022 Nov 30;14(47):52691-52701. (PMID: 36382954)
J Drug Target. 2019 Jun - Jul;27(5-6):646-658. (PMID: 30601085)
Sci Rep. 2014 Jun 04;4:5128. (PMID: 24894817)
Nat Biotechnol. 2010 Feb;28(2):172-6. (PMID: 20081866)
Nat Commun. 2021 Dec 13;12(1):7233. (PMID: 34903741)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Cytotechnology. 1997 Nov;25(1-3):45-52. (PMID: 22358878)
Mol Cancer. 2021 Feb 16;20(1):33. (PMID: 33593376)
Acta Biomed. 2020 Mar 19;91(1):157-160. (PMID: 32191675)
NPJ Vaccines. 2024 Mar 6;9(1):53. (PMID: 38448450)
Sci Rep. 2021 Jan 8;11(1):72. (PMID: 33420136)
J Colloid Interface Sci. 2024 Apr 15;660:66-76. (PMID: 38241872)
Curr Opin Immunol. 2020 Aug;65:14-20. (PMID: 32244193)
J Control Release. 2016 Apr 28;228:9-19. (PMID: 26941035)
Curr Top Microbiol Immunol. 2022;440:111-145. (PMID: 32300916)
ACS Nano. 2019 May 28;13(5):4947-4959. (PMID: 30964270)
J Control Release. 2018 Sep 28;286:20-32. (PMID: 30017722)
Nanomaterials (Basel). 2021 Jun 07;11(6):. (PMID: 34200384)
Cell Immunol. 2020 Aug;354:104143. (PMID: 32563850)
Clin Vaccine Immunol. 2008 Oct;15(10):1497-504. (PMID: 18753338)
فهرسة مساهمة: Keywords: Intranasal vaccination; Nanoparticles; Polymeric nanocapsule; SARS-CoV-2; mRNA vaccine
المشرفين على المادة: 0 (Nanocapsules)
0 (mRNA Vaccines)
0 (Emulsions)
0 (COVID-19 Vaccines)
MR86K0XRQP (1,2-dioleoyloxy-3-(trimethylammonium)propane)
0 (Quaternary Ammonium Compounds)
0 (Fatty Acids, Monounsaturated)
0 (RNA, Messenger)
0 (Drug Carriers)
تواريخ الأحداث: Date Created: 20240529 Date Completed: 20240626 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11208213
DOI: 10.1007/s13346-024-01635-5
PMID: 38811465
قاعدة البيانات: MEDLINE
الوصف
تدمد:2190-3948
DOI:10.1007/s13346-024-01635-5